Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effect and safety of anaprazole in the treatment of duodenal ulcers: a randomized, rabeprazole-controlled, phase III non-inferiority study

Published:2022-12-20 Issue:24 Volume:135 Page:2941-2949
ISSN:0366-6999
Container-title:Chinese Medical Journal
language:en
Short-container-title:

Author:

Zhu Huiyun,Pan Xue,Zhang Li,Sun Hongxin,Fan Huizhen,Pan Zhongwei,Huang Caibin,Shi Zhenwang,Ding Jin,Wang Qi,Du Yiqi,Lyu Nonghua,Li Zhaoshen

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine,General Medicine

Reference23 articles.

1. Epidemiology of peptic ulcer disease: endoscopic results of the systematic investigation of gastrointestinal disease in China;Li;Am J Gastroenterol,2010

2. Diagnosis and treatment of peptic ulcer disease;Kavitt;Am J Med,2019

3. 25 years of proton pump inhibitors: A comprehensive review;Strand;Gut Liver,2017

4. Potent potassium-competitive acid blockers: a new era for the treatment of acid-related diseases;Oshima;J Neurogastroenterol Motil,2018

5. Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?;Chey;Dig Dis Sci,2010

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Absorption, Metabolism, and Excretion of [¹⁴C]‐Labeled Anaprazole: A New Proton Pump Inhibitor, After a Single Oral Administration in Healthy Chinese Male Subjects;Clinical Pharmacology in Drug Development;2024-08-05

2. Integrated models of population pharmacokinetics and exposure response to optimize dosage regimen for anaprazole sodium in duodenal ulcer;European Journal of Pharmaceutical Sciences;2024-07

3. Cost-effectiveness analysis of Anaprazole versus Ilaprazole for the treatment of duodenal ulcers in China;Frontiers in Pharmacology;2024-06-07

4. Safety, Tolerability, and Pharmacokinetics of Anaprazole, a Novel Proton Pump Inhibitor, in Healthy Chinese Subjects;Clinical Pharmacology in Drug Development;2024-04-17

5. Forging a distinctive Chinese identity and pursuing global excellence: introducing the Chinese Medical Journal;Hong Kong Medical Journal;2023-12-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3